Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
PepsiCo Becomes a Dividend King
12:08pm, Tuesday, 24'th May 2022 The Motley Fool
The beverage and snack giant will finally attain that coveted status when it pays its next dividend in June.
AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate
03:46pm, Monday, 23'rd May 2022 Zacks Investment Research
AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
02:33pm, Monday, 23'rd May 2022 Benzinga
Upgrades
According to Morgan Stanley, the prior rating for Motorola Solutions Inc (NYSE:MSI) was changed from Equal-Weight to Overweight. Motorola Solns earned $1.70 in the first quarter, compared to
What 8 Analyst Ratings Have To Say About AbbVie
01:05pm, Monday, 23'rd May 2022 Benzinga
Within the last quarter, AbbVie (NYSE:ABBV) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
4
3
1
0
Last 30D
0
0
0
Is Twilio Stock Just Selling a Commodity?
11:00am, Sunday, 22'nd May 2022 The Motley Fool
Here's why Twilio has a competitive advantage.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
01:00pm, Friday, 20'th May 2022 Zacks Investment Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide
12:50pm, Friday, 20'th May 2022 Zacks Investment Research
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).
These 3 Stocks Have Doubled Over the Past 3 Years. Can They Do It Again?
10:40am, Thursday, 19'th May 2022 The Motley Fool
These three solid companies have the financial strength to drive their shares higher.
Vertex (VRTX) Outperforms Industry This Year So Far: Here's Why
01:06pm, Wednesday, 18'th May 2022 Zacks Investment Research
Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.
Is It Too Late to Buy AbbVie Stock?
03:23pm, Tuesday, 17'th May 2022 The Motley Fool
The bears think it's time to take profits and leave. But are they right?
AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug
01:27pm, Tuesday, 17'th May 2022 Zacks Investment Research
AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene
3 Dividend Stocks That Should Pay You for the Rest of Your Life
01:13pm, Monday, 16'th May 2022 The Motley Fool
Even the most aggressive, high-risk investment approach can benefit from passive income.
3 Supercharged Dividend Stocks to Buy in the Stock Market Sell-Off
02:30pm, Saturday, 14'th May 2022 The Motley Fool
Dividend stocks are a safe haven for investors in a period of market turmoil.
Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update
12:10pm, Friday, 13'th May 2022 Zacks Investment Research
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.
1 Company Disrupting Plastic Surgery, Not Patients
11:49am, Friday, 13'th May 2022 The Motley Fool
InMode's sales and profits have boomed, but you wouldn't know it from the company's share price.
